The cohort is a microarray-based gene expression test from pretreatment breast cancer biopsies (310 patients) to predict favorable outcome based on estrogen receptor (ER) status, pathologic response to chemotherapy, 3-year disease outcomes, and sensitivity to endocrine therapy. Here, ESR1 is linked to breast carcinoma.